Nothing Special   »   [go: up one dir, main page]

AR117228A1 - DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION - Google Patents

DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION

Info

Publication number
AR117228A1
AR117228A1 ARP190103517A ARP190103517A AR117228A1 AR 117228 A1 AR117228 A1 AR 117228A1 AR P190103517 A ARP190103517 A AR P190103517A AR P190103517 A ARP190103517 A AR P190103517A AR 117228 A1 AR117228 A1 AR 117228A1
Authority
AR
Argentina
Prior art keywords
independently selected
alkyl
nhr10
halogen
treatment
Prior art date
Application number
ARP190103517A
Other languages
Spanish (es)
Inventor
Kenneth Mcormack
Gregory Henkel
Michael Bruno Plewe
Vidyasagar Reddy Gantla
Nadezda Sokolova
Eric Brown
Original Assignee
Arisan Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisan Therapeutics filed Critical Arisan Therapeutics
Publication of AR117228A1 publication Critical patent/AR117228A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos heterocíclicos utilizables en el tratamiento de infecciones por arenavirus e infecciones víricas mediadas por glicoproteínas de arenavirus. Reivindicación 1: Un compuesto de fórmula estructural (1), o una sal farmacéuticamente aceptable y un portador, diluyente o vehículo farmacéuticamente aceptable del mismo, en donde A se selecciona independientemente entre C y N; G se selecciona independientemente entre CH, CD y N; E se selecciona independientemente entre CH, CD y N; J se selecciona independientemente entre los restos de fórmula (2) y (3); R² se selecciona independientemente entre H, D, -OR³, -R⁴, -NHR¹⁰, -CONHR¹⁰; R³ se selecciona independientemente entre H, D, alquilo C₁₋₆, alquenilo C₂₋₆, -NHC(O)R⁴, -C(O)NHR¹⁰ y -C(O)R¹⁰, en donde cada alquilo C₁₋₆ está opcionalmente sustituido con D, halógeno, -OH, -OR⁴, -NHR¹⁰; R⁴ se selecciona independientemente entre alquilo C₁₋₆ y cicloheteroalquilo C₂₋₉ opcionalmente sustituido con D, halógeno, -OH, -OR¹⁰ y NHR¹⁰; R⁵ se selecciona independientemente entre H, D, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, halógeno, -OR³, -CO₂R¹⁰, -NHC(O)R⁴, -C(O)NHR¹⁰, -NHR¹⁰, -CHNHR¹⁰, -CN, -CR⁴ y -C(O)R¹⁰, en donde cada alquilo C₁₋₆ está opcionalmente sustituido con D; R⁶ se selecciona independientemente entre H, D, halógeno, -OR³ y R⁴; R⁹ se selecciona independientemente entre H, D, halógeno, -OR¹⁰ y alquilo C₁₋₆; R¹⁰ se selecciona independientemente entre H, D, -OH, alquilo C₁₋₆ y alquenilo C₂₋₆; y cuando E es N, CH o CD, entonces A es C, G es CH o CD y J es el resto de fórmula (2); y cuando A es N, entonces J es el resto de fórmula (3); con la condición de que se excluyan los compuestos: seleccionados del grupo de fórmulas (4).Heterocyclic compounds usable in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins. Claim 1: A compound of structural formula (1), or a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier, diluent or vehicle thereof, wherein A is independently selected from C and N; G is independently selected from CH, CD, and N; E is independently selected from CH, CD, and N; J is independently selected from the residues of formula (2) and (3); R² is independently selected from H, D, -OR³, -R⁴, -NHR¹⁰, -CONHR¹⁰; R³ is independently selected from H, D, C₁₋₆ alkyl, C₂₋₆ alkenyl, -NHC (O) R⁴, -C (O) NHR¹⁰, and -C (O) R¹⁰, wherein each C₁₋₆ alkyl is optionally substituted with D, halogen, -OH, -OR⁴, -NHR¹⁰; R⁴ is independently selected from C₁₋₆ alkyl and C₂₋₉ cycloheteroalkyl optionally substituted with D, halogen, -OH, -OR¹⁰ and NHR¹⁰; R⁵ is independently selected from H, D, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, halogen, -OR³, -CO₂R¹⁰, -NHC (O) R⁴, -C (O) NHR¹⁰, -NHR¹⁰, - CHNHR¹⁰, -CN, -CR⁴, and -C (O) R¹⁰, wherein each C₁₋₆ alkyl is optionally substituted with D; R⁶ is independently selected from H, D, halogen, -OR³, and R⁴; R⁹ is independently selected from H, D, halogen, -OR¹⁰, and C₁₋₆ alkyl; R¹⁰ is independently selected from H, D, -OH, C₁₋₆ alkyl, and C₂₋₆ alkenyl; and when E is N, CH or CD, then A is C, G is CH or CD and J is the remainder of formula (2); and when A is N, then J is the remainder of formula (3); provided that compounds are excluded: selected from the group of formulas (4).

ARP190103517A 2018-12-06 2019-12-02 DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION AR117228A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06

Publications (1)

Publication Number Publication Date
AR117228A1 true AR117228A1 (en) 2021-07-21

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103517A AR117228A1 (en) 2018-12-06 2019-12-02 DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION

Country Status (11)

Country Link
EP (1) EP3890731A4 (en)
JP (1) JP2022509763A (en)
KR (1) KR20210106997A (en)
CN (1) CN113329750A (en)
AR (1) AR117228A1 (en)
AU (1) AU2019393784A1 (en)
BR (1) BR112021010909A2 (en)
CA (1) CA3118765A1 (en)
EA (1) EA202191001A1 (en)
MX (1) MX2021005234A (en)
WO (1) WO2020117794A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040068613A (en) * 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 Deuterated compound and composition for treating hypertension
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CA2864484C (en) * 2012-02-17 2019-07-02 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Also Published As

Publication number Publication date
JP2022509763A (en) 2022-01-24
CA3118765A1 (en) 2020-06-11
WO2020117794A1 (en) 2020-06-11
CN113329750A (en) 2021-08-31
AU2019393784A1 (en) 2021-05-27
EP3890731A4 (en) 2022-08-17
KR20210106997A (en) 2021-08-31
MX2021005234A (en) 2021-08-11
EP3890731A1 (en) 2021-10-13
BR112021010909A2 (en) 2021-08-24
EA202191001A1 (en) 2021-08-16

Similar Documents

Publication Publication Date Title
AR108710A1 (en) FXR MODULAR COMPOUNDS (NR1H4)
PE20230376A1 (en) DIACYL GLYCEROL KINASE MODULATING COMPOUNDS
AR127309A2 (en) PYRDAZINONE DERIVATIVES
AR115296A1 (en) HETEROCYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR THE TREATMENT OF CANCER
AR106037A1 (en) MODULATORS OF THE CORE PROTEIN OF HEPATITIS B
AR110405A1 (en) COMPOUNDS
AR095430A1 (en) PIRIMIDINE AND PIRIDINE COMPOUNDS AND THEIR USE AS INHIBITORS OF FGFR ACTIVITY
AR103064A1 (en) FXR MODULATING COMPOUNDS (NR1H4)
AR114793A1 (en) MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES OF THEM
AR119657A1 (en) PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME
AR123355A1 (en) APOL1 INHIBITORS AND METHODS OF USING THE SAME
AR111594A1 (en) INHIBITING AGENTS OF THE TUTOSINA QUINASA DE BRUTON
AR108175A1 (en) TIAZOL ACETAMIDA ANTIVÍRICOS COMPOUNDS
AR111814A1 (en) USEFUL FORMIMIDAMIDE COMPOUNDS AGAINST PHYTOOPATHOGEN MICROORGANISMS
PE20081113A1 (en) POLYCYCLIC VIRAL INHIBITORS
AR120556A1 (en) HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE
AR117228A1 (en) DERIVATIVES OF PYRAZOLE [1,2-a] PYRIDINE, 1H-BENZO [d] [1,2,3] TRIAZOL, IMIDAZOPYRIMIDINE AND BENZIMIDAZOLE FOR USE IN THE TREATMENT OF ARENAVIRUS INFECTION
AR112794A1 (en) HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE IN THE TREATMENT OF DISEASES INDUCED BY IDH MUTATIONS
AR108845A1 (en) DERIVATIVES OF [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE AS MODULATORS OF THE CB2 RECEIVER
AR125365A1 (en) 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS
AR108327A1 (en) SUBSTITUTED FUSIONATED PYRIMIDINONE COMPOUNDS
AR111826A1 (en) BICYCLIC COMPOUNDS 5.6 FUSIONATES AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
AR122336A1 (en) HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE
AR126733A1 (en) NICOTINAMIDE RIPK1 INHIBITORS
AR121282A1 (en) NAMPT MODULATORS